How alpha‑1 receptor changes affect unborn babies' brain blood flow
The role of Alpha1-Adrenergic Receptors Promoter Methylation in Cerebral Autoregulation in Fetus
This work looks at whether changes in alpha‑1 adrenergic receptors explain why preterm babies cannot protect their brains from sudden blood‑pressure surges.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11295384 on NIH RePORTER |
What this research studies
From a patient’s perspective, researchers are studying why very early (preterm) fetuses fail to reduce blood flow to the brain when blood pressure rises, which can lead to vessel rupture and brain injury. They use fetal lamb models to compare near‑term and preterm responses, measuring carotid artery constriction and brain blood flow. The team examines alpha‑1 adrenergic receptor levels and promoter methylation and tests effects of removing sympathetic input and applying receptor agonists on isolated artery segments. Findings aim to link receptor expression and epigenetic changes to the immature blood‑flow control seen in preterm infants.
Who could benefit from this research
Good fit: This research is most relevant to parents and clinicians of very preterm infants at risk for cerebral blood‑flow instability and hemorrhage.
Not a fit: Patients without prematurity‑related cerebral autoregulation problems or those already at term are unlikely to directly benefit from this preclinical work.
Why it matters
Potential benefit: If successful, this work could point to biological targets that help prevent brain hemorrhage in preterm infants by improving brain blood‑flow control.
How similar studies have performed: Related animal and ex‑vivo studies have shown that alpha‑1 adrenergic signaling affects arterial constriction, but linking promoter methylation to fetal cerebral autoregulation is relatively new.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Goyal, Ravi — University of Arizona
- Study coordinator: Goyal, Ravi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.